about
Current developments in pharmacological therapeutics for chronic constipationClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic targetChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsDiets for constipationResearch and progress on ClC‑2 (Review).Recent advances in pharmacological treatment of irritable bowel syndrome.Effects of lubiprostone on pacemaker activity of interstitial cells of cajal from the mouse colon.Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndromeStimulation of Mucin, Mucus, and Viscosity during Lubiprostone in Patients with Chronic Constipation may Potentially Lead to Increase of Lubrication.Novel amino-carbonitrile-pyrazole identified in a small molecule screen activates wild-type and ΔF508 cystic fibrosis transmembrane conductance regulator in the absence of a cAMP agonistA randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.Direct interactions between ENaC gamma subunit and ClCN2 in cystic fibrosis epithelial cells.Alteration of the Intestinal Environment by Lubiprostone Is Associated with Amelioration of Adenine-Induced CKD.ClC-1 chloride channels: state-of-the-art research and future challenges.A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.Prokinetic effects of large-dose lubiprostone on gastrointestinal transit in dogs and its mechanismsAddition of Lubiprostone to polyethylene glycol(PEG) enhances the quality & efficacy of colonoscopy preparation: a randomized, double-blind, placebo controlled trial.Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epitheliaLubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice.Novel therapeutic approaches in IBS.Recent developments in the therapy of irritable bowel syndrome.Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon.Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced ConstipationComparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine.Emerging drugs for chronic constipation.Functional constipation in childhood: current pharmacotherapy and future perspectives.Management of constipation in Parkinson's disease.Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders.Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84.Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota.Role of lubiprostone on gastrointestinal motility.New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group.Long-Term Safety and Efficacy of Lubiprostone in Opioid-induced Constipation in Patients with Chronic Noncancer Pain.Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes.Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation.Opioid-induced constipation.
P2860
Q27025474-EE9BDC2F-7103-4266-BF90-2A025427E7F3Q28066092-587EFDF7-35C1-4EBD-BB57-294E729DE2C5Q28079705-C6161C74-7C2C-4A9D-BB56-3DB033394F01Q28086802-CC0964E1-2A7D-4AC7-9770-EBD14839F583Q33828111-0FF687A5-9E82-478B-BC0B-7983E4CEDA18Q33958853-6E8678D8-2BE8-4945-8849-8ECB140E83EDQ34097910-F28B07B5-15DF-4FBD-AFE1-ECFE42B12213Q34345704-663AC1B7-1BDF-41A9-9C70-739F831B024AQ34760189-5B57C908-96E4-4346-B1D8-95D50E304BD2Q34780067-B90F1FD4-BDB6-43A8-A973-EA34F6B8315EQ34805216-A35819B7-6F00-444E-9A5C-670C58E2CB58Q35294275-897B590E-EF81-4F6A-BD30-B1A6ABDD1522Q35530569-3819ACAC-387A-4068-A23D-2AA7558491BCQ35541006-CED97CC2-53B9-420A-923A-C4CCDAC52B89Q35583262-98532422-7857-4EE0-8F52-389BD4E8B4E8Q35662982-A4A225E8-1BF3-4EF2-87C8-2E9048FF502AQ36163072-CFC3B5C9-2F68-4C7E-94AB-F1A003E4D4E6Q36371798-F72BAB1C-D8A5-41B3-8875-9DFA49281C8CQ36699974-FE8AFE50-1971-488E-A5B1-6F9A10ECBB43Q36977287-57E09B74-62BB-49E3-9026-D8AFE20E3511Q37002201-A7145185-B5B3-486F-857B-860465DC7F7CQ37071175-1A8A75DB-BA92-4E85-AFBB-B41BF25565FDQ37162424-7F656A6D-9F37-413C-9D90-73F810B248E1Q37233788-99FF9E65-2886-4E8F-9C18-08516C083150Q37383155-485C7E52-4713-418D-9CB6-0CF5F34B2016Q37570550-253F6435-B13D-4CA6-9B7A-F20F3185B8D8Q38065282-0C3430D6-CD0A-437E-8BF2-D8B54987A567Q38300388-8C8F81E4-D21C-45EA-8705-DA9D3D6E5B49Q38604426-866705DF-B011-431E-9B31-9E348F8FBCD7Q39622609-3B417B11-222C-4868-915C-A60D40390970Q39646395-53735E12-C8F7-4DAE-A59A-EF3BEB2F4122Q41811753-B42E82E9-1946-416B-9EEC-365F34D9C353Q42695148-705B846A-A9DB-41FA-AE3F-50BCAF3CD1EDQ43062741-ED7F10A6-0C5B-4DB8-A7CA-B9E0E081566DQ44331744-DACA641A-9AF1-462F-9017-25AE7490C2D2Q44349621-E3B18DF7-DB6A-470E-8E2A-EC7324296236Q46203792-4A9B4309-EBD5-4394-A532-1950CAA14C8CQ54262333-ABC69B7C-A26B-465D-AFCB-7F1466609B84
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Lubiprostone: a chloride channel activator.
@en
type
label
Lubiprostone: a chloride channel activator.
@en
prefLabel
Lubiprostone: a chloride channel activator.
@en
P1476
Lubiprostone: a chloride channel activator.
@en
P2093
Brian E Lacy
L Campbell Levy
P304
P356
10.1097/01.MCG.0000225665.68920.DF
P577
2007-04-01T00:00:00Z